CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
Identifieur interne : 000E66 ( Ncbi/Merge ); précédent : 000E65; suivant : 000E67CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
Auteurs : Michael R. Pranzatelli [États-Unis] ; Anna L. Travelstead ; Elizabeth D. Tate ; Tyler J. Allison ; Steven J. VerhulstSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Adolescent, Antigens, CD19 (cerebrospinal fluid), Antigens, CD19 (immunology), Antigens, CD5 (cerebrospinal fluid), Antigens, CD5 (immunology), B-Lymphocytes, Biological Markers, Brain Neoplasms (complications), Child, Child, Preschool, Female, Flow Cytometry, Humans, Immunophenotyping, Infant, Lymphocyte Subsets, Male, Neuroblastoma (complications), Paraneoplastic Syndromes, Nervous System (cerebrospinal fluid), Paraneoplastic Syndromes, Nervous System (complications), Paraneoplastic Syndromes, Nervous System (immunology), Severity of Illness Index, Videotape Recording.
- MESH :
- chemical , cerebrospinal fluid : Antigens, CD19, Antigens, CD5.
- chemical , immunology : Antigens, CD19, Antigens, CD5.
- cerebrospinal fluid : Paraneoplastic Syndromes, Nervous System.
- complications : Brain Neoplasms, Neuroblastoma, Paraneoplastic Syndromes, Nervous System.
- immunology : Paraneoplastic Syndromes, Nervous System.
- Adolescent, B-Lymphocytes, Biological Markers, Child, Child, Preschool, Female, Flow Cytometry, Humans, Immunophenotyping, Infant, Lymphocyte Subsets, Male, Severity of Illness Index, Videotape Recording.
Abstract
Lack of a biomarker of disease activity has hindered the therapy of childhood opsoclonus-myoclonus syndrome (OMS), which is purported to be mediated humorally. To determine if the cerebrospinal fluid (CSF) B lymphocyte, which may traffic into the central nervous system (CNS) to produce antibody locally, is one such biomarker, B lymphocytes were immunophenotyped in the CSF and blood of 56 children with OMS and 26 pediatric controls by dual-laser flow cytometry. Neurological severity was rated blindly from videotapes using a validated 12-item motor evaluation scale. Children with OMS manifested a 4- to 7-fold higher percentage of total B-cells in CSF (P < 0.0001), including CD5(+) (P = 0.001) and CD5(-) (P = 0.0004) B-cell subsets, compared with controls, in whom the percentages were negligible and unchanging with age. CSF expansion of both B-cell subsets increased with disease severity and decreased with disease duration (P
DOI: 10.1002/mds.20125
PubMed: 15254934
DOI: 10.1002/mds.20125
PubMed: 15254934
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003418
- to stream PubMed, to step Curation: 003418
- to stream PubMed, to step Checkpoint: 003538
Links to Exploration step
pubmed:15254934Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.</title><author><name sortKey="Pranzatelli, Michael R" sort="Pranzatelli, Michael R" uniqKey="Pranzatelli M" first="Michael R" last="Pranzatelli">Michael R. Pranzatelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. mpranzatelli@siumed.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643</wicri:regionArea><wicri:noRegion>Illinois 62794-9643</wicri:noRegion></affiliation></author><author><name sortKey="Travelstead, Anna L" sort="Travelstead, Anna L" uniqKey="Travelstead A" first="Anna L" last="Travelstead">Anna L. Travelstead</name></author><author><name sortKey="Tate, Elizabeth D" sort="Tate, Elizabeth D" uniqKey="Tate E" first="Elizabeth D" last="Tate">Elizabeth D. Tate</name></author><author><name sortKey="Allison, Tyler J" sort="Allison, Tyler J" uniqKey="Allison T" first="Tyler J" last="Allison">Tyler J. Allison</name></author><author><name sortKey="Verhulst, Steven J" sort="Verhulst, Steven J" uniqKey="Verhulst S" first="Steven J" last="Verhulst">Steven J. Verhulst</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15254934</idno><idno type="pmid">15254934</idno><idno type="doi">10.1002/mds.20125</idno><idno type="wicri:Area/PubMed/Corpus">003418</idno><idno type="wicri:Area/PubMed/Curation">003418</idno><idno type="wicri:Area/PubMed/Checkpoint">003538</idno><idno type="wicri:Area/Ncbi/Merge">000E66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.</title><author><name sortKey="Pranzatelli, Michael R" sort="Pranzatelli, Michael R" uniqKey="Pranzatelli M" first="Michael R" last="Pranzatelli">Michael R. Pranzatelli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. mpranzatelli@siumed.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643</wicri:regionArea><wicri:noRegion>Illinois 62794-9643</wicri:noRegion></affiliation></author><author><name sortKey="Travelstead, Anna L" sort="Travelstead, Anna L" uniqKey="Travelstead A" first="Anna L" last="Travelstead">Anna L. Travelstead</name></author><author><name sortKey="Tate, Elizabeth D" sort="Tate, Elizabeth D" uniqKey="Tate E" first="Elizabeth D" last="Tate">Elizabeth D. Tate</name></author><author><name sortKey="Allison, Tyler J" sort="Allison, Tyler J" uniqKey="Allison T" first="Tyler J" last="Allison">Tyler J. Allison</name></author><author><name sortKey="Verhulst, Steven J" sort="Verhulst, Steven J" uniqKey="Verhulst S" first="Steven J" last="Verhulst">Steven J. Verhulst</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Antigens, CD19 (cerebrospinal fluid)</term><term>Antigens, CD19 (immunology)</term><term>Antigens, CD5 (cerebrospinal fluid)</term><term>Antigens, CD5 (immunology)</term><term>B-Lymphocytes</term><term>Biological Markers</term><term>Brain Neoplasms (complications)</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Flow Cytometry</term><term>Humans</term><term>Immunophenotyping</term><term>Infant</term><term>Lymphocyte Subsets</term><term>Male</term><term>Neuroblastoma (complications)</term><term>Paraneoplastic Syndromes, Nervous System (cerebrospinal fluid)</term><term>Paraneoplastic Syndromes, Nervous System (complications)</term><term>Paraneoplastic Syndromes, Nervous System (immunology)</term><term>Severity of Illness Index</term><term>Videotape Recording</term></keywords><keywords scheme="MESH" type="chemical" qualifier="cerebrospinal fluid" xml:lang="en"><term>Antigens, CD19</term><term>Antigens, CD5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, CD19</term><term>Antigens, CD5</term></keywords><keywords scheme="MESH" qualifier="cerebrospinal fluid" xml:lang="en"><term>Paraneoplastic Syndromes, Nervous System</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Brain Neoplasms</term><term>Neuroblastoma</term><term>Paraneoplastic Syndromes, Nervous System</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Paraneoplastic Syndromes, Nervous System</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>B-Lymphocytes</term><term>Biological Markers</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Flow Cytometry</term><term>Humans</term><term>Immunophenotyping</term><term>Infant</term><term>Lymphocyte Subsets</term><term>Male</term><term>Severity of Illness Index</term><term>Videotape Recording</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lack of a biomarker of disease activity has hindered the therapy of childhood opsoclonus-myoclonus syndrome (OMS), which is purported to be mediated humorally. To determine if the cerebrospinal fluid (CSF) B lymphocyte, which may traffic into the central nervous system (CNS) to produce antibody locally, is one such biomarker, B lymphocytes were immunophenotyped in the CSF and blood of 56 children with OMS and 26 pediatric controls by dual-laser flow cytometry. Neurological severity was rated blindly from videotapes using a validated 12-item motor evaluation scale. Children with OMS manifested a 4- to 7-fold higher percentage of total B-cells in CSF (P < 0.0001), including CD5(+) (P = 0.001) and CD5(-) (P = 0.0004) B-cell subsets, compared with controls, in whom the percentages were negligible and unchanging with age. CSF expansion of both B-cell subsets increased with disease severity and decreased with disease duration (P </div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15254934</PMID><DateCreated><Year>2004</Year><Month>07</Month><Day>15</Day></DateCreated><DateCompleted><Year>2004</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>7</Issue><PubDate><Year>2004</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.</ArticleTitle><Pagination><MedlinePgn>770-7</MedlinePgn></Pagination><Abstract><AbstractText>Lack of a biomarker of disease activity has hindered the therapy of childhood opsoclonus-myoclonus syndrome (OMS), which is purported to be mediated humorally. To determine if the cerebrospinal fluid (CSF) B lymphocyte, which may traffic into the central nervous system (CNS) to produce antibody locally, is one such biomarker, B lymphocytes were immunophenotyped in the CSF and blood of 56 children with OMS and 26 pediatric controls by dual-laser flow cytometry. Neurological severity was rated blindly from videotapes using a validated 12-item motor evaluation scale. Children with OMS manifested a 4- to 7-fold higher percentage of total B-cells in CSF (P < 0.0001), including CD5(+) (P = 0.001) and CD5(-) (P = 0.0004) B-cell subsets, compared with controls, in whom the percentages were negligible and unchanging with age. CSF expansion of both B-cell subsets increased with disease severity and decreased with disease duration (P </AbstractText><CopyrightInformation>Copyright 2004 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pranzatelli</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. mpranzatelli@siumed.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Travelstead</LastName><ForeName>Anna L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Tate</LastName><ForeName>Elizabeth D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Allison</LastName><ForeName>Tyler J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Verhulst</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018956">Antigens, CD5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018941">Antigens, CD19</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018956">Antigens, CD5</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001402">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005434">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016130">Immunophenotyping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016131">Lymphocyte Subsets</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009447">Neuroblastoma</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020361">Paraneoplastic Syndromes, Nervous System</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000134">cerebrospinal fluid</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014743">Videotape Recording</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>11</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15254934</ArticleId><ArticleId IdType="doi">10.1002/mds.20125</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Allison, Tyler J" sort="Allison, Tyler J" uniqKey="Allison T" first="Tyler J" last="Allison">Tyler J. Allison</name><name sortKey="Tate, Elizabeth D" sort="Tate, Elizabeth D" uniqKey="Tate E" first="Elizabeth D" last="Tate">Elizabeth D. Tate</name><name sortKey="Travelstead, Anna L" sort="Travelstead, Anna L" uniqKey="Travelstead A" first="Anna L" last="Travelstead">Anna L. Travelstead</name><name sortKey="Verhulst, Steven J" sort="Verhulst, Steven J" uniqKey="Verhulst S" first="Steven J" last="Verhulst">Steven J. Verhulst</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Pranzatelli, Michael R" sort="Pranzatelli, Michael R" uniqKey="Pranzatelli M" first="Michael R" last="Pranzatelli">Michael R. Pranzatelli</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000E66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15254934
|texte= CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15254934" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |